Minerva Surgical, Inc. engages in the research, development, manufacture, and commercialization of invasive solutions for uterine healthcare needs of women. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in manufacturing and distribution of invasive gynecologic technologies. The firm is focused on improving women's health and quality of life by providing access to minimally invasive, technologically advanced, and innovative solutions for early detection, treatment, and management of uterine conditions. The company delivers devices that treat the root causes of Abnormal Uterine Bleeding (AUB) in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and Disposable Hysteroscope. Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology. Symphion System is designed to transform the way you see and remove uterine fibroids and polyps.
Follow-Up Questions
Minerva Surgical Inc (UTRS)'in P/E oranı nedir?
Minerva Surgical Inc 'in P/E oranı 0 'dir
Minerva Surgical Inc 'in CEO'su kimdir?
Mr. Todd Usen 2023 'den beri şirketle birlikte olan Minerva Surgical Inc 'in President 'ıdır.
UTRS hissesinin fiyat performansı nasıl?
UTRS 'in mevcut fiyatı $0.0001 'dir, son işlem günde 0% decreased etti.
Minerva Surgical Inc için ana iş temaları veya sektörler nelerdir?
Minerva Surgical Inc Health Care endüstrisine ait ve sektör Health Care 'dir
Minerva Surgical Inc 'in mevcut piyasa değerlemesi $888 'dir
Minerva Surgical Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Minerva Surgical Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
